We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.28%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$86.6M
(+30%)
Cap. Flow
+$68.5M
Cap. Flow
% of AUM
18.43%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
36
New
15
Increased
5
Reduced
8
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$18.6M |
| 2 |
Cigna
CI
|
+$17.2M |
| 3 |
AET
Aetna Inc
AET
|
+$17.1M |
| 4 |
Perrigo
PRGO
|
+$16.2M |
| 5 |
HNT
HEALTH NET INC
HNT
|
+$15.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$16.5M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$15.7M |
| 3 |
AKRX
Akorn Inc
AKRX
|
+$14.3M |
| 4 |
Intuitive Surgical
ISRG
|
+$13.9M |
| 5 |
United Therapeutics
UTHR
|
+$12.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.04% |
| 2 | Miscellaneous | 11.8% |
| 3 | Financials | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$74.7B
| $20.1M | 5.42% |
+124,312
| New | +$17.2M |
|
|
AET
2
DELISTED
Aetna Inc
AET
| $19.1M | 5.15% |
+150,187
| New | +$17.1M |
|
|
3
Humana
HUM
$48.2B
| $19.1M | 5.15% |
+100,000
| New | +$18.6M |
|
4
Cooper Companies
COO
$13.6B
| $18M | 4.85% |
404,920
+164,920
| +69% | +$7.43M |
|
5
Centene
CNC
$33.1B
| $17M | 4.56% |
421,656
-78,344
| -16% | -$2.81M |
|
|
HNT
6
DELISTED
HEALTH NET INC
HNT
| $16.4M | 4.41% |
+255,814
| New | +$15.3M |
|
7
Viatris
VTRS
$19.4B
| $16.3M | 4.38% |
240,000
-30,000
| -11% | -$2.12M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $15.9M | 4.27% |
65,638
-1,862
| -3% | -$462K |
|
|
9
Perrigo
PRGO
$2.07B
| $15.7M | 4.23% |
+85,000
| New | +$16.2M |
|
|
RCPT
10
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $15.2M | 4.09% |
80,000
-30,000
| -27% | -$4.96M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $14.9M | 4.02% |
325,000
+40,000
| +14% | +$1.9M |
|
12
Vertex Pharmaceuticals
VRTX
$138B
| $14.2M | 3.82% |
115,000
+10,000
| +10% | +$1.26M |
|
13
BioMarin Pharmaceuticals
BMRN
$12.9B
| $12.9M | 3.48% |
94,665
+7,165
| +8% | +$888K |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.6M | 3.39% |
+69,590
| New | +$12M |
|
15
Acadia Pharmaceuticals
ACAD
$4.83B
| $12.6M | 3.38% |
+300,000
| New | +$11.6M |
|
|
CPHD
16
DELISTED
Cepheid Inc
CPHD
| $12.5M | 3.37% |
205,064
+5,064
| +3% | +$289K |
|
17
Alkermes
ALKS
$7.73B
| $12.1M | 3.25% |
187,500
-47,500
| -20% | -$2.91M |
|
18
Edwards Lifesciences
EW
$51.8B
| $11.7M | 3.14% |
490,968
-109,032
| -18% | -$2.46M |
|
19
Nektar Therapeutics
NKTR
$2.53B
| $11.6M | 3.11% |
+61,667
| New | +$10.6M |
|
|
ALR
20
DELISTED
Alere Inc
ALR
| $11.3M | 3.05% |
215,000
-10,000
| -4% | -$503K |
|
21
Teva Pharmaceuticals
TEVA
$42.4B
| $10.3M | 2.78% |
175,000
-30,000
| -15% | -$1.85M |
|
|
SIRO
22
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
| $10M | 2.7% |
+100,000
| New | +$9.6M |
|
|
THOR
23
DELISTED
THORATEC CORPORATION
THOR
| $9.58M | 2.58% |
+215,000
| New | +$9.41M |
|
24
Smith & Nephew
SNN
$12.1B
| $9.34M | 2.51% |
+275,000
| New | +$9.55M |
|
|
WMGI
25
DELISTED
Wright Medical Group Inc
WMGI
| $9.19M | 2.47% |
+350,000
| New | +$9.25M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
AIM
KFS
Blue Jay Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Blue Jay Capital Management held 36 positions worth $372M, up 30% from $285M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Blue Jay Capital Management deployed $68.5M of net new capital in Q2 2015, opening 15 new positions and adding to 5 existing holdings. Its largest new stake was Humana: 100,000 shares worth $19.1M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $4.96M trimmed.
- Blue Jay Capital Management's largest Q2 2015 buy was Humana: 100,000 shares worth $19.1M.
- Blue Jay Capital Management added most to Cooper Companies in Q2 2015, an estimated $7.43M increase.
- Blue Jay Capital Management's biggest Q2 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $4.96M.
- Blue Jay Capital Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q2 2015, selling an estimated $16.5M.
- Blue Jay Capital Management's ten largest holdings make up 47% of its $372M portfolio in Q2 2015.
- Blue Jay Capital Management opened 15 new positions and closed 8 in Q2 2015.
- Blue Jay Capital Management's portfolio value rose 30% quarter-over-quarter to $372M.
Based on Blue Jay Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.